Clinical Trial News Archive - April 2010
Get news by email or subscribe to our news feeds.
April 2, 2010
- Cardioxyl Pharmaceuticals' Data Presented At American College Of Cardiology (Acc) Annual Scientific Sessions
- Pharming Group N.V. (NL) - Pharming's C1 inhibitor effective in preventing AMR in animal model of transplant rejection
- Report: A Drug That Extends Life Span Prevents Alzheimer's Deficits
April 5, 2010
- Biogen Idec Strengthens Position as a Leader in Neurology with 38 Data Presentations at 62nd Annual Meeting of the American Academy of Neurology
- SCYNEXIS Announces Acceptance of Abstracts Related to its Hepatitis C Clinical Candidate, SCY-635, for Presentation at 45th Annual Meeting of the European Association for the Study of the Liver
- Peregrine Pharmaceuticals Reports Data From Newly Published Research Reinforcing Potential of Targeting PS in HIV Infection
- Webcast Alert: PMX-30063 Phase 1B Clinical Study Results
April 6, 2010
- Researchers Discover Weak Link in Alzheimer?s Drug Candidates
- AVANIR Pharmaceuticals to Present Zenvia Phase III Data at American Academy of Neurology Annual Meeting
- Opexa to Present Tovaxin Data at the American Academy of Neurology 2010 Annual Meeting
- AVANIR Pharmaceuticals to Present Zenvia Phase III Data at American Academy of Neurology Annual Meeting
April 7, 2010
- Report from LCT's Russian Phase I/IIa Diabetes Trial
- Synta Announces Poster Presentations at the American Association for Cancer Research Annual Meeting
- MAP Pharmaceuticals to Report Additional Subpopulation Data From FREEDOM-301 Trial at the Annual Meeting of the American Academy of Neurology
- PolyMedix Reschedules Webcast for Wednesday, April 7 at 10:00 AM
- Teva to Present New Data on Multiple Sclerosis and Parkinson's Disease at the 62nd American Academy of Neurology Annual Meeting
- New England Journal of Medicine Publishes PROVE 3 Trial Showing Telaprevir-Based Regimens Significantly Increased Sustained Viral Response (SVR) Rates in Patients Who Did Not Achieve SVR with Prior HCV Therapy
April 8, 2010
- Presidio Pharmaceuticals, Inc. to Present at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL)
- Cempra Pharmaceuticals Will Present New Data on CEM-101 and TAKSTA (CEM-102) at the 20th European Congress of Clinical Microbiology and Infectious Disease
- New Diclofenac Formulation Offers Novel Route to Fast Relief From Migraine Symptoms
- Extensive Neupro (Rotigotine Transdermal System) Data to be Presented at the 62nd American Academy of Neurology Meeting in Toronto, Canada
- Oncolytics Biotech® Inc. Announces Publication of Preclinical Research on Combination of Antiangiogenic Cancer Therapy with Oncolytic Virotherapy
- New Tβ4 Eye Data to be Presented at ARVO Meeting
- Celgene Cellular Therapeutics Announces Top-Line Results from First Clinical Study with Placenta-Derived Cells (PDA-001)
April 9, 2010
- Abraxis to Present Phase I/II Pancreatic Survival Data at 101st Annual Meeting of the American Association for Cancer Research
- AAN Data Show UCB's Neupro Effective and Safe in Late- and Early-stage Parkinson's and RLS
- Idera Pharmaceuticals Presents Data on Anti-Atherogenic Effects of Toll-like Receptor Antagonist in Preclinical Model of Atherosclerosis at American Heart Association Conference
- CPP-109 Clinical Trial Data to be Presented at the American Society of Addiction Medicine Annual Medical-Scientific Conference
- Research Supporting the Role of Antiepileptic Drug Vimpat (Lacosamide) (C-V) to be Highlighted at Upcoming AAN Meeting
- Data on XOMA 052 to be Presented at the American Association of Cancer Research Annual Meeting
- Regado Biosciences, Inc. Presents the First Clinical Experience with REG2, its Second Product Candidate, at the Arteriosclerosis, Thrombosis and Vascular Biology Scientific Sessions in San Francisco, CA on April 9, 2010.
- Both H5N1 Bird Flu and H1N1 Swine Flu Replikin Counts Are Increasing
- GE Healthcare Presents Positive Phase 2 Data with Flutemetamol - Phase 3 Program Now Underway
- Finkelstein Thompson LLP Announces Investigation of Medivation, Inc.
- New Study Finds Three in Ten Women Take Common Breast Cancer Drug to Treat Infertility
April 12, 2010
- Rib-X to Present Data on Delafloxacin at European Congress of Clinical Microbiology and Infectious Diseases
- Inhibitex Reports Results of Interim Analysis of Phase II Clinical Trial of FV-100
- XenoPort Announces Presentations of New Data for Arbaclofen Placarbil and XP13512 at American Academy of Neurology Meeting
- Angiochem to Present Data for Oncology Programs at American Association for Cancer Research Meeting
April 13, 2010
- Data from AVEO Pharmaceuticals' Translational Research Platform and Novel Antibody Pipeline to be Presented at AACR 101st Annual Meeting 2010
- Acorda Therapeutics Announces Data on AMPYRA (dalfampridine) Presented at American Academy of Neurology Meeting
- Preclinical Data on ARIAD's Oncology Pipeline to Be Presented at the AACR Annual Meeting
- VBL Therapeutics to Present Data from VB-201 and VB-111 at Prominent Cancer Research and Dermatology Medical Meetings
- Novartis Investigational Multiple Sclerosis Therapy Gilenia (FTY720) Shown To Reduce Relapse Rates Regardless Of Treatment History
- AVANIR Pharmaceuticals Presents Zenvia Long-Term Efficacy Data at AAN Annual Meeting Late Breaking Science Program
- Baxter and New York-Presbyterian/Weill Cornell Announce 18-Month Data from Phase II Study of GAMMAGARD in Patients with Alzheimer's Disease
April 14, 2010
- CombinatoRx Discovers Novel Multi-Target Mechanism for the Treatment of Hematologic Malignancies
- Inovio Biomedical to Present at World Vaccine Congress 2010
- 12 Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2010 ASCO Annual Meeting
- Rexahn Announces Phase IIa Study Results of Serdaxin in MDD
- Merz Pharmaceuticals Announces Long-Term Efficacy and Safety Data with Repeated Xeomin Injections in Upper Limb Post-Stroke Spasticity
- New analysis assesses impact of common genetic variation on benefit of antiplatelet therapy
- Large Body of Data on Tysabri to Be Presented at Annual Meeting of the American Academy of Neurology
- Rexahn Pharmaceuticals Issues Additional Comments and Clarifications on its Phase IIa Study Results of Serdaxin in Major Depressive Disorder (MDD)
- Encouraging data from three Astex collaborative programmes to be presented at the 101st American Association for Cancer Research (AACR) Annual Meeting 2010
April 15, 2010
- AVANIR Pharmaceuticals Presents Zenvia Phase III Safety Data at the American Academy of Neurology Annual Meeting
- Statins May Slow Progression Of Multiple Sclerosis, New Study Finds
- Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme's Phase 2 Trial Remain Free of Clinically-Active Disease
- Comparative Trial of Canyon's Iprivask (Desirudin) with Standard of Care Shows Favorable Outcomes for Thrombosis Prophylaxis in Surgery Patients with HIT
- Zealand Pharma (DK) - Positive Phase III Diabetes Data with Lixisenatide Announced by Zealand Pharma's Partner sanofi-aventis
- Remicade Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
- Synosia's SYN-115 Demonstrates Clinical Benefit in Parkinson's Disease
- Peregrine's Bavituximab & Apoptosis-Inducer Eradicates Cancer in Breast Cancer Model
- Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Days in Phase 1b Trial
- SCYNEXIS' SCY-635 Demonstrates Impressive Barrier to Resistance in HCV Treatment
- Experimental Immune Boosting Drug Worsens TB in Mice
- Dynavax's Chronic Kidney Disease Study Confirms HEPLISAV's Enhanced Seroprotection Against HBV Infection
- AVANIR Pharmaceuticals Presents Zenvia Phase III Safety Data at the American Academy of Neurology Annual
April 16, 2010
- Affymax and Takeda Report Phase 2 Analyses of Hematide/peginesatide in Hemodialysis Patients
- Ocera Therapeutics Presents Data on the Prevalence of Mild Hepatic Encephalopathy Defined as Neurocognitive Impairment in Patients with Liver Cirrhosis at EASL Annual Meeting
- Avila Presents Preclinical Data on Two Novel, Orally-Available Protease Inhibitors, AVL-181 and AVL-192, for Hepatitis C Infection at EASL 2010 Meeting
- AMD Alliance International: First-Ever Estimates of Global Cost of Vision Loss Reported Today
- Circadian's VGX-100 Significantly Inhibits Tumour Growth in Animal Models of Human Cancer
- Kenta Biotech Reports 100% Survival with Panobacumab in Life-Threatening Hospital-Acquired Pneumonia
- Idera Pharmaceuticals Announces Positive Phase 1 Data of IMO-2125 in Null Responder HCV Patients at EASL 2010
- Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-8243 at the American Association for Cancer Research
- Romark Announces Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C
- OctoPlus N.V. (NL) - Improved tolerability profile of Locteron confirmed by data presented at EASL conference
- Pharmasset Announces Interim Data from an Ongoing 28-day Phase 2a Study with PSI-7977 for the Treatment of Chronic Hepatitis C Infection
- New Data Supporting Cladribine Tablets as a Potential New Therapeutic Option Presented at the 62nd AAN Annual Meeting
- Genzyme Study of Myozyme Treatment for Pompe Disease Published in New England Journal of Medicine
- Arthritis Impacts African-Americans and Hispanics More than Whites
- SCYNEXIS Presents In Vitro Toxicity Study Suggesting that SCY-635 is Unique in the Cyclophilin Inhibitor Class
- ArQule Presentations at AACR 101St Annual Meeting Focus on Development of Oncology Pipeline
- Knopp Neurosciences Presents Further Encouraging Trends in Its Phase 2 Study of KNS-760704 (Dexpramipexole) in ALS
- Idenix Pharmaceuticals Reports Favorable Pharmacokinetic Data for IDX320, a Potent, Multi-Genotypic Protease Inhibitor for the Treatment of Hepatitis C
- 59 Percent of Patients Overall Achieved SVR with Telaprevir-Based Regimens in Study 107 After Not Achieving SVR with at Least One Prior Course of Treatment for Hepatitis C Virus Infection
- CombinatoRx to Present Data for Oncology Programs at American Association for Cancer Research Meeting
April 19, 2010
- New Analysis of Prana's Clinical Trial is Published in the Journal of Alzheimer's Disease
- Antisoma plc (UK) - AACR presentations highlight potential of Antisoma drugs AS1413 and AS1411
- RXi Pharmaceuticals Presents at AACR Conference, Highlighting the Potential for RNAi Therapeutics in Oncology
- BioSante Pharmaceuticals, Inc. To Present and Participate in Cancer Immunotherapy Panel at the World Vaccine Congress
- ADAGIO Analysis Demonstrates That the Natural Progression of Clinical Symptoms in Parkinson's Disease May Be Slower in Earlier Stages
- Study shows potential benefit of dark chocolate for liver disease patients
- VBL Therapeutics Announces Preclinical and Clinical Data Demonstrating Substantial Tumor Reduction and Stable Disease Achieved with First-in-Class Vascular Disruptive Agent in Advanced Cancers
- Celldex Announces Presentation at 101st Annual AACR Meeting
- MiRNA-21 Linked to Tumor Suppressor Loss, Herceptin Resistance
- Jennerex Presents Positive Data from Trial of JX-594 for Liver Cancer at EASL
- New Preclinical Breast Cancer Study Shows Peregrine's PS-Targeting Antibodies Can Reverse Tumor-Induced Immune Suppression
- AACR Study Show Peregrine's PS-Targeting Antibodies Reverse Tumor-Induced Immune Suppression
- NewLink Genetics Presents Positive Phase1/2 Data on HyperAcute(R)-Lung Cancer Immunotherapy
- Novelos Therapeutics and Academic Collaborators Present Three Posters at AACR 2010 Annual Meeting
- Octapharma Trial on Intravenous Immunoglobulin (IVIG) in Alzheimer's Disease at ICAD 2010 Congress
- Positive Interim Results for JX-594 Randomized Phase 2 Liver Cancer Trial Presented at Major International Conference (EASL)
- Synta Presents STA-9090 Results at AACR Including Synergy with Avastin, Tarceva, and Taxanes; Downregulation of HIF-1a; Inhibition of JAK/STAT
- Medivir: TMC435 Was Presented in Four Posters at the International Liver Congress 2010 by EASL, April 14-18, 2010
- Abraxane in Combination with Gemcitabine Increases Survival in First-Line Treatment of Advanced Pancreatic Cancer in Phase I/II Study
- Stallergenes: Positive Results for Oralair Phase III Trial in the USA
- XOMA 052 Shows Potent In Vitro Inhibition of Interleukin-6 Production in Human Myeloma Cells
April 20, 2010
- Human Genome Sciences and GlaxoSmithKline Announce Topline 76-Week Results of Phase 3 Trial of Benlysta in Systemic Lupus Erythematosus
- AcelRx Sufentanil NanoTab PCA System (ARX-01) Phase 2 Results Featured in Poster Presentations at the 35th Annual Meeting of the American Society of Regional Anesthesia and Pain to be held in Toronto on April 22-25th.
- Biovest to Present at World Vaccine Congress 2010
- Alnylam and Collaborators Demonstrate Regression of Pathogenic Transthyretin (TTR) Amyloid Deposits Following Treatment with an RNAi Therapeutic in an Animal Model of TTR-Mediated Amyloidosis (ATTR)
- Orion Oyj (FI) - Dexmedetomidine Phase III program completed with positive results
- Celsion Announces Oral Presentation of Phase I ThermoDox Data At 2010 IHPBA World Congress
- QLT Announces Positive Interim Results From Phase 1b Study of its Oral Synthetic Retinoid Compound in Leber Congenital Amaurosis
- ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for the Non-Surgical Treatment of Symptomatic Vitreomacular Adhesion (VMA)
- Phenomix Announces Positive Results from a Phase 3 Study of Dutogliptin in Type 2 Diabetes Mellitus
- Synta Presents Results at AACR Supporting Correlative Markers for Elesclomol Activity
- Genta Presents Initial Clinical Data on Use of Gallium Compounds as Treatment for Serious Infections
- Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada and Tibotec Pharmaceuticals' TMC278
- Genta Presents Initial Clinical Data on Use of Gallium Compounds as Treatment for Serious Infections
- Gene Test Shows Who Could Benefit From Statins to Reduce Colon Cancer Risk: Study
- Mersana Therapeutics Presents Data Demonstrating XMT-1001 Substantially Accumulates in Tumor and Results in Significantly Prolonged Drug Exposure
- Systemic and Antigen-Specific Immune Responses in Patients Treated With Cancer Vaccine BPX-101 Correlate With Clinical Response
- Plexxikon's PLX3397 Preclinical Data Demonstrate Potential of Novel, ?First-in-Class? Cancer Drug
- Karmanos Cancer Institute Researchers Study Novel Folate Transporter to Customize Chemotherapy
- Third Candidate from Esperance's Targeted Anti-cancer Platform, EP-302, Establishes Preclinical Proof of Concept
- Angiochem Presents Data Further Demonstrating the Role of LRP-1 in Cancer
- ABRAXANE in Combination with Bevacizumab Shows Promise in New Model of Triple Negative Breast Cancer
- Advaxis Chairman/CEO Thomas A. Moore to Present at the World Vaccine Congress 2010
- Semafore Pharmaceuticals Commences Phase I Expansion Study of Novel Dual PI3K-mTOR Inhibitor in B-Cell Malignancies
- ARIAD Presents Preclinical Data on Its Investigational ALK Inhibitor, AP26113, Demonstrating That It Can Overcome Mutation-Based Drug Resistance in Cancer Models
- Aeterna Zentaris Presents a Poster on its Dual Inhibitors for PI3K and Erk, as well as an Oral Presentation Reporting Data on Selective Erk Inhibitors, at AACR Annual Meeting
April 21, 2010
- Alchemia's HyACT Technology Enhances the Killing of Cancer Stem Cell Populations in Breast and Colorectal Cancer
- Groundbreaking Research on Management of Cardiometabolic Syndrome to be Unveiled at Scientific Conferences in Anaheim, CA, April 23-28
- Basilea Pharmaceutica AG (CH) - New research data on Basilea's novel oncology drug candidate presented
- Curis Presents Preclinical Data on CU-906 at AACR 101st Annual Meeting 2010
- Seattle Genetics and Agensys, an Affiliate of Astellas, Report ASG-5ME Preclinical Data at AACR
- Seattle Genetics Highlights ADC and SEA Technologies at AACR
- 3 Peregrine AACR presentations show breadth of PS-targeting applications
- Three Presentations at AACR Annual Meeting Show Breadth of Applications for Peregrine's Innovative Phospholipid-Targeting Technologies
- Tumors Deficient in a Specific Enzyme Are Sensitive to a New Drug 'ADI-PEG 20'
- Results of Phase II trial of NGR-hTNF in mesothelioma published by the Journal of Clinical Oncology
- PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
- Spectrum Pharmaceuticals Announces Belinostat Data Presentation at 101st Annual Meeting of the American Association for Cancer Research
- AVEO Pharmaceuticals' Selective Anti-Notch1 Monoclonal Antibody Exhibits Potent Notch1 Inhibitory Activity
- Agios Scientists Present IDH1 Data at 2010 AACR Meeting
- Celldex Presents Data for Novel Cancer Antibody Program at 101st Annual AACR Meeting
April 22, 2010
- Geron Gives Five Presentations on Telomerase Inhibitor Imetelstat at the AACR Annual Meeting
- Curis Publishes Preclinical CUDC-101 Data in Cancer Research
- Foresight Biotherapeutics Announces Presentation at the 2010 Association for Research in Vision and Ophthalmology
- ZIOPHARM Palifosfamide PICASSO Trial Abstract Selected for 2010 Best of ASCO Meeting Program
- Hunter Immunology: International Medical Experts Recognise Benefit Of Australian COPD Treatment
- Vical Presents Encouraging Preliminary Data From Final 12-month Follow-up in TransVax CMV Vaccine Phase 2 Transplant Recipient Trial
- Blood Test Enables Heart-Transplant Recipients to Undergo Fewer Biopsies, Stanford Study Shows
April 23, 2010
- Pfizer Discontinues Phase 3 Trial of Sutent in Advanced Hepatocellular Carcinoma
- miRagen Therapeutics' Chief Scientific Advisor to Give Plenary Lecture at Joint Meeting of the American Society for Clinical Investigation and the Association of American Physicians
- Lancet publishes data demonstrating superior efficacy of Victoza compared to Januvia
- NattoPharma (NO) - Vitamin K experts critical towards simplified message from Emaus' study
- The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
- RXi Pharmaceuticals to Deliver Presentations at Upcoming Conferences Outlining the Development and Progression of its Next Generation rxRNA? Therapeutic Platform
- Enzon Presents Data at 2010 AACR Meeting
- Advanced Cell Technology's Studies to Support Phase I Multicenter Trial of Patients with Stargardt's Macular Dystrophy Demonstrate Excellent Safety Profile
- New Data Pesented At AACE Showed Welchol Significantly Improved Lipid & Glycemic Measures In Prediabetes Patients
- Friday News Highlights from the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting and Clinical Congress
- Affymax Announces Self-Imposed Quiet Period as the Company Analyzes Phase 3 Results for Hematide/peginesatide
- Study Shows AFREZZA Controls Blood Sugar Levels in Type 1 Diabetes, Results in Weight Loss, Less Hypoglycemia Than Usual Care
- New Data Demonstrate Welchol (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes
- Follow-up Safety Data Show AFREZZA Comparable to Standard Antidiabetic Therapy in Lung Function Tests
April 26, 2010
- Symphogen Announces Publication in Molecular Biotechnology of Sympress II Production System Allowing Single-Batch Recombinant Polyclonal Antibody Manufacturing
- Pevion Announces Excellent Preclinical Results for PEV4 RSV Vaccine Candidate
- Alkermes to Provide Update on Advancing Product Portfolio and Proprietary Platforms at R&D Day
- Biotie Reports Positive Top-line Data from Clinical Study with its Third Generation Oral PDE4 Inhibitor - ELB353 is Well Tolerated and Shows Clear Pharmacological Activity
- Wake Up to Nocturia - Studies Reinforce Serious Associated Risk of Nocturia
April 27, 2010
- Vical Reports Encouraging Updates From U.S. Military Malaria Vaccine Programs
- Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
- Compparative-Effectiveness Study Confirms New Treatment for Diabetic Macular Edema
April 28, 2010
- Adamas Pharmaceuticals' Triple Combination Antiviral Drug (TCAD) Therapy is Well Tolerated in a Pilot Study of Immunocompromised Patients With Influenza A
- Merely Seeing Disease Symptoms May Promote Aggressive Immune Response
- Immune Cells Predict Success of Head and Neck Cancer Treatment, U-M Study Finds
- Basilea Pharmaceutica Ag (Ch) - Basilea's Toctino Included In Expert Consensus For Management Of Chronic Hand Eczema In France
- Study shows why cholesterol damages arteries
- Mount Sinai researchers discover potential treatment for bone death in the hip from osteonecrosis
April 29, 2010
- TxCell announces positive preliminary results from the phase I/IIa clinical trial of OvaSave in Crohn's disease
- Pre-Clinical Results Show NexACT Technology Significantly Improves Subcutaneous Delivery and Anti-Metastatic Activity of Angstrom's A6 Cancer Compound
- Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation
- Independent Panel Finds Insufficient Evidence to Support Preventive Measures for Alzheimer's Disease
- Novavax's Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
- Bioject Announces Results of Intradermal Dose Sparing Influenza Study Conducted by the Centers for Disease Control and Prevention
- EnzymeRx Announces Strong Phase 1 Results for Pegsitacase
- Cancer Risk the Same for Kidney Transplant Recipients, No Matter the Drug
- BioMarin Reports Positive Results for Phase I/II Trial for BMN 110 for MPS IVA
April 30, 2010
- Journal of Clinical Oncology Publishes Data on Overall Survival Benefit of VELCADE (Bortezomib) for Injection in Patients with Previously Untreated Multiple Myeloma
- Protein loss in the urine harmful for people with high blood pressure
- Antibiotic regimen effective for reactive arthritis
- VaxInnate Announces Phase II Data
